Exeliom Biosciences develops innate immune modulators intended to restore immune responsiveness in cancer, inflammatory disease and chronic infection. Its lead candidate EXL01 is a bacterial-derived, NOD2-targeting immunomodulator that activates macrophages and reprograms the immune microenvironment. EXL01 is in three Phase 2 oncology trials in combination with immune checkpoint inhibitors, a Phase 2 trial in Crohn's disease and a Phase 2 trial for prevention of recurrent Clostridioides difficile infection. The company was formerly named Nextbiotix.